



H.E.L Group appoints Kevin O'Donovan as Chair

Appointment brings significant Board and commercial experience to deliver sustainable company growth

Borehamwood, UK, 07 April 2020: H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety and scale-up, today announced the appointment of Kevin O'Donovan as Chair of the H.E.L Board of Directors. Kevin takes over from interim Chair, Jon Andrew, and will guide the Company to deliver sustainable growth while continuing to help customers solve complex scientific challenges.

Kevin is a Business Angel and has built up a portfolio of investments in the life sciences over the last 20 years, sitting on a number of Boards as Chair or Non-Executive Director. Several of these companies have been successfully sold, with listings on Ofex and AIM.

Previously, Kevin founded the molecular biology instrumentation company, Hybaid, and directed its growth from concept to trade sale for £12 million. Here his expertise lay in export, and he successfully implemented a global network of 40 companies. Kevin has an MBA which he obtained from the UK's Kingston Business School.


The announcement of the new Chair follows a number of recent leadership team appointments and builds on the Company's strong growth initiatives and focus on strengthening production and service support.

Louise Madden, CEO of H.E.L Group commented: *"Through these uncertain times, H.E.L is continuing to invest in the best talent with the most relevant experience as we scale and grow. I would like to thank Jon for his great support as Interim Chair, at the same time as welcoming Kevin to the team. With significant Board and commercial experience in the scientific sector, Kevin is ideally placed to make sure that the company is taking the right measures to deliver sustainable growth for our investors whilst doing the right things for our employees and our customers."*

Kevin O'Donovan, Chair, H.E.L Group, commented: *"H.E.L has a clear vision that through collaboration we can play a significant role in unleashing the potential of the scientific community. We have the ability to solve complex challenges for customers and continue to drive enterprise value. As such, I am very excited to join a great team of skilled scientists and engineers and look forward to driving continued success."*

ENDS

Notes to Editors



Kevin O'Donovan, Chair, H.E.L Group

For high-resolution images, please contact Zyme Communications.

For further information please contact:

Zyme Communications

Sarah Jeffery

Tel: +44 (0)7771 730919

E-mail: sarah.jeffery@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please [click here](#).

About H.E.L. Group www.helgroup.com

H.E.L Group's mission is to work together with chemistry, safety and biotechnology experts to engineer and unleash the full potential of the scientific community. To this end, H.E.L develops and manufactures innovative scientific instruments and software designed to optimize the efficiency, safety and productivity of key processes in chemistry and biology applications.

The H.E.L team of 70 includes highly skilled process and software engineers, based at their extensive research and manufacturing facilities in the UK, as well as sales and support offices around the world.

H.E.L has a long history of solving complex challenges for customers. For more than 30 years the Company has worked with businesses and laboratories globally, providing proprietary automated solutions for the pharma, biotechnology, chemical, battery and petrochemical sectors.

Following significant growth, and with annual revenues exceeding £10 million, the Company is extending the reach of its products to support and enable R&D and process optimization further across the US, China and India.